Business NewsPR NewsWire • Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals

Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals

Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals

MISSISSAUGA, ON, Nov. 3, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it plans to commence a Phase 3 clinical study of Pennsaid 2% for the treatment of acute pain to...

View More : http://www.prnewswire.com/news-releases/nuvo-research-plans-phase-3-study-of-pennsaid-2-to-support-international-regulat...
Releted News by prnewswire
Superior Business Solutions Middle East SBS Announced Today Joining Hands with MeCareer to Provide Healthcare IT Outsourcing Service
On-premise solutions to give way to hosted and cloud-based UC solutions in Australia, says Frost & Sullivan
Consumers worry about privacy but still willing to share data
Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals
El foro "Future Energy" marca el comienzo de la preparación del contenido científico de la EXPO-2017
Accelerite Joins OpenStack Foundation as a Corporate Sponsor